QURE vs. CRVS
QURE (uniQure N.V.) and CRVS (Corvus Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, QURE returned 11.46%/yr vs 0.06%/yr for CRVS. At a 0.29 correlation, their price movements are largely independent.
Performance
QURE vs. CRVS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, QURE achieves a 15.21% return, which is significantly lower than CRVS's 54.94% return. Over the past 10 years, QURE has outperformed CRVS with an annualized return of 11.46%, while CRVS has yielded a comparatively lower 0.06% annualized return.
QURE
- 1D
- 2.80%
- 1M
- -5.49%
- YTD
- 15.21%
- 6M
- 41.31%
- 1Y
- 72.42%
- 3Y*
- 10.96%
- 5Y*
- -5.23%
- 10Y*
- 11.46%
CRVS
- 1D
- 2.84%
- 1M
- -24.68%
- YTD
- 54.94%
- 6M
- 42.53%
- 1Y
- 181.37%
- 3Y*
- 53.32%
- 5Y*
- 33.63%
- 10Y*
- 0.06%
QURE vs. CRVS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
QURE uniQure N.V. | 15.21% | 35.50% | 160.86% | -70.14% | 9.31% | -42.60% | -49.58% | 148.65% | 47.12% | 249.82% |
CRVS Corvus Pharmaceuticals, Inc. | 54.94% | 43.93% | 203.98% | 107.06% | -64.73% | -32.30% | -34.56% | 48.23% | -64.58% | -27.55% |
Correlation
The correlation between QURE and CRVS is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.34 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.29 |
Correlation (All Time) Calculated using the full available price history since Mar 23, 2016 | 0.29 |
Fundamentals
QURE:
$1.73B
CRVS:
$1.07B
QURE:
-$3.58
CRVS:
-$0.53
QURE:
11.58
CRVS:
4.46
QURE:
$18.09M
CRVS:
$0.00
QURE:
$13.42M
CRVS:
-$26.00K
QURE:
-$164.53M
CRVS:
-$47.43M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
QURE vs. CRVS — Risk / Return Rank
QURE
CRVS
QURE vs. CRVS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for uniQure N.V. (QURE) and Corvus Pharmaceuticals, Inc. (CRVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| QURE | CRVS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.74 | ||
| Sortino ratioReturn per unit of downside risk | -1.26 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.48 | -0.03 |
| Calmar ratioReturn relative to maximum drawdown | 0.83 | 3.23 | -2.40 |
| Martin ratioReturn relative to average drawdown | 1.35 | 7.03 | -5.68 |
Loading charts...
Drawdowns
QURE vs. CRVS - Drawdown Comparison
The maximum QURE drawdown since its inception was -95.40%, roughly equal to the maximum CRVS drawdown of -96.97%. Use the drawdown chart below to compare losses from any high point for QURE and CRVS.
Loading charts...
Drawdown Indicators
| QURE | CRVS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.40% | -96.97% | +1.57% |
Max Drawdown (1Y)Largest decline over 1 year | -87.21% | -56.43% | -30.78% |
Max Drawdown (3Y)Largest decline over 3 years | -87.21% | -70.50% | -16.71% |
Max Drawdown (5Y)Largest decline over 5 years | -90.11% | -92.40% | +2.29% |
Max Drawdown (10Y)Largest decline over 10 years | -95.40% | -96.97% | +1.57% |
Current DrawdownCurrent decline from peak | -66.46% | -53.25% | -13.21% |
Average DrawdownAverage peak-to-trough decline | -56.61% | -69.28% | +12.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 53.75% | 25.91% | +27.84% |
Volatility
QURE vs. CRVS - Volatility Comparison
uniQure N.V. (QURE) and Corvus Pharmaceuticals, Inc. (CRVS) have volatilities of 24.13% and 23.12%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| QURE | CRVS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.13% | 23.12% | +1.01% |
Volatility (6M)Calculated over the trailing 6-month period | 92.07% | 111.88% | -19.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 273.03% | 180.64% | +92.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 154.02% | 131.02% | +23.00% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 119.76% | 111.13% | +8.63% |
Dividends
QURE vs. CRVS - Dividend Comparison
Neither QURE nor CRVS has paid dividends to shareholders.
Financials
QURE vs. CRVS - Financials Comparison
This section allows you to compare key financial metrics between uniQure N.V. and Corvus Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
QURE and CRVS have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
QURE has higher volatility (24.13%) compared to CRVS (23.12%). In terms of maximum drawdown, QURE dropped -95.40% vs CRVS's -96.97%.
CRVS currently has the higher Sharpe Ratio (1.01 vs 0.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for QURE and CRVS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer